Mackenzie Financial Boosts Bristol Myers Squibb Stake by 13.6%

Asset manager increases holding in pharmaceutical company to over 1.2 million shares

Mar. 13, 2026 at 10:05am

Got story updates? Submit your updates here. ›

Mackenzie Financial Corp, a major asset management firm, has increased its stake in Bristol Myers Squibb Company by 13.6% in the third quarter of 2026. The firm now owns 1,254,471 shares of the biopharmaceutical company's stock, worth approximately $56.6 million.

Why it matters

This investment move by Mackenzie Financial highlights the firm's confidence in Bristol Myers Squibb's long-term prospects. As a major shareholder, Mackenzie's increased stake signals that the asset manager believes the pharmaceutical company is well-positioned to deliver strong returns for investors.

The details

According to a 13F filing with the SEC, Mackenzie Financial purchased an additional 149,701 shares of Bristol Myers Squibb during the third quarter. This brings the firm's total ownership in the company to about 0.06% of the outstanding shares. The increased stake was part of Mackenzie's broader strategy to boost its exposure to the biopharmaceutical sector.

  • Mackenzie Financial increased its Bristol Myers Squibb stake in the third quarter of 2026.

The players

Mackenzie Financial Corp

A major Canadian asset management firm that oversees over $200 billion in client assets.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on developing and delivering innovative medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

Mackenzie Financial's increased stake in Bristol Myers Squibb underscores the asset manager's confidence in the pharmaceutical company's ability to deliver value for shareholders over the long term. This investment move highlights the firm's bullish outlook on the biopharmaceutical industry as a whole.